Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

MorphoSys AG, DE0006632003

MorphoSys AG, DE0006632003

21.05.2021 - 15:03:10

MorphoSys To Participate in UBS Global Healthcare Conference

or www.morphosys-us.com.

Monjuvi(R) is a registered trademark of MorphoSys AG. Tremfya(R) is a registered trademark of Janssen Biotech, Inc.For more information, please contact:

? Media Contacts: Thomas Biegi Vice President Tel.: +49 (0)89 / 89927 26079thomas.biegi@morphosys.com Investor Contacts: Dr. Julia Neugebauer Senior Director Tel: +49 (0)89 / 899 27 179julia.neugebauer@morphosys.com Jeanette Bressi Director, US Communications Tel: +1 617-404-7816jeanette.bressi@morphosys.com Myles Clouston Senior Director Tel: +1 857-772-0240myles.clouston@morphosys.com ?


21.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg

Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1199495 ? End of News DGAP News Service


@ dgap.de